Long-term oral antiarrhythmic therapy, attempting to maintain sinus rhythm, is warranted for some patients with atrial fibrillation (AF) and severe symptoms, even though efficacy is limited and proarrhythmia is a concern. Class IC agents, including flecainide and propafenone, are well tolerated at the usual dosages. The class III agent sotalol has β-blocking activity that may be useful in specific cases. Despite serious side effects, amiodarone can provide a reasonable balance of benefit and risk with proper patient selection, dosing, and follow-up. In the absence of specific contraindications, anticoagulant therapy to prevent thromboembolism is warranted for all patients with AF. Warfarin is recommended for high-risk patients; aspirin is appropriate for those at low risk.
|Original language||English (US)|
|Number of pages||11|
|Journal||Journal of Critical Illness|
|State||Published - Jun 16 1999|
ASJC Scopus subject areas
- Critical Care and Intensive Care Medicine